BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
About BIND
We are a clinical-stage nanomedicine platform company developing ACCURINS®, a new class of targeted and programmable therapeutics developed using our Medicinal Nanoengineering® platform. ACCURINS are nanoparticles designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease, enhancing efficacy while minimizing adverse effects on healthy tissues. We are developing our own pipeline of ACCURINS, initially in oncology, as well as ACCURINS in collaboration with biopharmaceutical companies.

We believe ACCURINS represent the next stage in the evolution of cancer therapy. ACCURINS are designed to target tumors at three levels: tissue, cellular and molecular. They combine this triple targeting with a prolonged circulation time to concentrate the therapeutic payload at the targeted disease site, where it is then released in a controlled and timely manner. ACCURINS have the potential to significantly increase the net clinical benefit of the therapeutic payload and result in efficacy and safety not currently achievable through other therapeutic approaches.

Our lead drug candidate, BIND-014, is currently enrolling patients with squamous histology non-small cell lung cancer (NSCLC) in a Phase 2 clinical trial called iNSITE1. We are also evaluating BIND-014 in patients with urothelial carcinoma, cholangiocarcinoma, cervical cancer and squamous cell carcinoma of the head and neck in a second Phase 2 trial called iNSITE2. Our second proprietary drug candidate, BIND-510, is a prostate-specific membrane antigen (PSMA)-targeted ACCURIN nanoparticle containing vincristine and is currently in preclinical development. The company has collaborated or is collaborating with Pfizer, AstraZeneca, Roche, Merck, Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals, Inc.) and Amgen to develop ACCURINS based on therapeutic payloads and targeting ligands from their product pipelines.
We seek to significantly improve patients' lives and treat disease by developing ACCURINS.